Report looked great to me, increased revenues, more announcements,
Mid-2020 (Next month?)
Phase 3 randomized controlled trial of Revascor for advanced heart failure, final study visits for all surviving patients have been completed, ongoing quality review of all data is being completed at the study sites, with a data readout planned for mid-2020.
In the Phase 3 randomized controlled trial of MPC-06-ID for chronic low back pain due to degenerative disc disease, final study visits for all patients have been completed, ongoing quality review of all data is being completed at the study sites, with a data readout planned for mid-2020
This should really determine how the SP moves forward.
Report looked great to me, increased revenues, more...
-
- There are more pages in this discussion • 615 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.28 |
Change
-0.030(2.29%) |
Mkt cap ! $1.461B | |||
| Open | High | Low | Value | Volume |
| $1.32 | $1.35 | $1.28 | $1.677M | 1.289M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 44452 | $1.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 23596 | 1 |
View Market Depth
| Last trade - 16.10pm 04/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |